Strong Response to SARS-CoV-2 vaccine additional doses among patients with inflammatory bowel diseases
Journal of Crohn's and Colitis
; 16:i586-i587, 2022.
Article
in English
| EMBASE | ID: covidwho-1722361
ABSTRACT
Background:
Current recommendations in many countries support additional COVID-19 vaccine doses in patients with inflammatory bowel disease (IBD) who are treated with immunosuppressants, yet real-world data on the effectiveness and safety of additional vaccine doses is lacking. We sought to quantify the humoral immune response to an additional vaccine dose in patients with IBD.Methods:
We performed a direct-to-patient, internet-based cohort study of patients with IBD in the United States who have received any SARS-CoV-2 vaccine granted EUA. Participants completed baseline and follow-up surveys and had blood work obtained approximately 8 weeks following completion of the initial vaccination series and 6 weeks following administration of an additional vaccine dose. We performed quantitative measurement of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2 using the LabCorp Cov2Quant IgG™ assay.Results:
A total of 659 participants were included [415 participants (63%) initially received BNT162b2, 243 participants (37%) initially received mRNA-1273, and 5 participants (1%) initially received Ad26.COV2.S]. Demographic, clinical, and treatment characteristics of the study population are provided in Table 1. Over 98% of those receiving an initial mRNA vaccine received the same type additional dose. Whereas 93% had detectable antibody after the initial vaccination series, 99.5% had detectable antibodies following an additional dose. Mean (SD) increase in antibody level was 61 ug/mL (103) in those receiving BNT162b2 and 78 ug/mL (143) for those receiving mRNA-1273 (Figure 1). Importantly, of 47 of patients without initial antibody response, 45 (96%) had detectable antibodies following an additional dose. Additional vaccination was generally well tolerated in this population, with 44%, 24%, 25%, and 6% reporting no, mild, moderate, and severe side effects respectively.Conclusion:
These findings demonstrate robust immunogenicity to additional doses of SARS-CoV-2 vaccine, even amongst patients with undetectable antibody following the initial series. Adverse event rates were low. These data can be used to inform vaccine decisions in patients with a broad array of immune-medicated conditions frequently managed by immunosuppression.
ad26.cov2.s vaccine; elasomeran; immunoglobulin G antibody; RNA vaccine; tozinameran; adult; antibody response; cohort analysis; conference abstract; controlled study; demography; drug therapy; female; follow up; human; humoral immunity; immunogenicity; immunosuppressive treatment; inflammatory bowel disease; Internet; major clinical study; male; nonhuman; quantitative analysis; receptor binding; Severe acute respiratory syndrome coronavirus 2; side effect; United States; vaccination
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Journal of Crohn's and Colitis
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS